Stuti Shroff

Stuti Shroff

Auto-generated profile, based on publicly available information

Stuti Shroff

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
OMOwen P. Martin
Owen P. Martin
MWMichael S. Wallace
Michael S. Wallace
COChristopher Oetheimer
Christopher Oetheimer
HPHailey B. Patel
Hailey B. Patel
EBEmma C. Butler
Emma C. Butler
NANadia Alatrakchi
Nadia Alatrakchi

1 February 2018 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
AWAnnika L. Windon
Annika L. Windon
ARTURO LOAIZA-BONILLAARTURO LOAIZA-BONILLA
ARTURO LOAIZA-BONILLA
CJChristopher Edward Jensen
Christopher Edward Jensen
MRMichael Randall
Michael Randall
JMJennifer J. D. Morrissette
Jennifer J. D. Morrissette
SSStuti G. Shroff
Stuti G. Shroff
Background: The KRAS oncogene is a driver mutation and is present in greater than 90% of pancreatic ductal adenocarcinomas (PDAC). A subset of these tumors, however, do not harbor mutations in KRAS (wild type KRAS). Studies have shown that patients with mutated KRAS have a poorer survival on first-line gemcitabine-based chemotherapy compared to wild type KRAS. In this study, we examined a cohort of patients with PDAC at our institution who were either wild type or mutant for the KRAS gene and assessed for differences in survival and response to different chemotherapeutic regimens. Methods: We examined clinical records of patients treated at the Abramson Cancer Center of the University of Pennsylvania from 2013 to 2017. Patients with a pancreatic mass and a histologic diagnosis of pancreatic or pancreaticobiliary adenocarcinoma were identified. Thirty-nine patients with PDAC who underwent tumor sequencing at Penn Medicine’s Center for Personalized Diagnostics (CPD) were selected for further study. Twelve patients were identified whose tumors were KRAS wild type. Twenty-seven patients with PDAC whose tumors harbored KRAS mutations were selected as controls (KRAS mutant). Results: We noted a longer overall survival (OS) among KRAS wild type patients compared to KRAS mutant patients (P=0.026). This was independent of the age at diagnosis, patient gender, stage of diagnosis, tumor morphology, mismatch repair (MMR) status, and chemotherapeutic regimen. Conclusions: Similar to previously reported studies, PDAC with a KRAS wild type mutational profile has a better prognosis with a longer OS. This improved prognosis is independent of the protocol utilized in therapy for these patients. Our findings suggest that future clinical trials in pancreatic cancer should take into consideration the presence of KRAS mutations in their pre-planned analysis when assessing the efficacy of a novel therapeutic approach. This may be a crucial factor in trial concepts and outcomes.

26 August 2022 in Science Advances
Verified
Journal Article
Open access
DLDarrick K. Li
Darrick K. Li
SCSnehal Nitin Chaudhari
Snehal Nitin Chaudhari
YLYoojin Lee
Yoojin Lee
MSMozhdeh Sojoodi
Mozhdeh Sojoodi
AAArijit A. Adhikari
Arijit A. Adhikari
ADA. Sloan Devlin
A. Sloan Devlin
Altered host-microbe interactions and increased intestinal permeability have been implicated in disease pathogenesis. However, the mechanisms by which intestinal microbes affect epithelial barrier integrity remain unclear. Here, we investigate the impact of bacterial metabolism of host-produced bile acid (BA) metabolites on epithelial barrier integrity. We observe that rats fed a choline-deficient, l -amino acid–defined, high-fat diet (CDAHFD) exhibit reduced intestinal abundance of host-produced conjugated BAs at early time points, coinciding with increased gut permeability. We show that in vitro, conjugated BAs protect gut epithelial monolayers from damage caused by bacterially produced unconjugated BAs through micelle formation. We then demonstrate that inhibition of bacterial BA deconjugation with a small-molecule inhibitor prevents the development of pathologic intestinal permeability and hepatic inflammation in CDAHFD-fed rats. Our study identifies a signaling-independent, physicochemical mechanism for conjugated BA-mediated protection of epithelial barrier function and suggests that rational manipulation of microbial BA metabolism could be leveraged to regulate gut barrier integrity.

13 November 2023 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SLSamantha J. Linder
Samantha J. Linder
TBTiziano Bernasocchi
Tiziano Bernasocchi
BMBárbara Martínez-Pastor
Bárbara Martínez-Pastor
KSKelly D. Sullivan
Kelly D. Sullivan
MGMatthew D. Galbraith
Matthew D. Galbraith
RMRaul Mostoslavsky
Raul Mostoslavsky

15 August 2017 in Case Reports in Pathology
Verified
Journal Article
Open access
PDF file
SSSharon J. Song
Sharon J. Song
SSStuti G. Shroff
Stuti G. Shroff
Idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV) is a rare disease characterized by intimal smooth muscle proliferation, leading to the thickening of small to medium-sized mesenteric veins. This vascular disease mimics inflammatory bowel disease (IBD) clinically and endoscopically, while showing ischemic mucosal changes without the classic features of IBD on biopsy. Given the mixed picture, this entity is frequently misdiagnosed. Surgical resection of the diseased bowel segment reveals the true etiology of the pathology and is curative. We describe a case of a 59-year-old man with a long-standing history of Crohn’s disease refractory to medical therapy and status after multiple small bowel resections. The patient underwent a subtotal abdominal colectomy with pathology showing dense, indurated mesenteric adipose tissue, significant muscularis propria hypertrophy, and myointimal hyperplasia of the mesenteric veins in a peri-ileal and pericolic distribution, as confirmed by elastin stain. No evidence of mucosal ischemic changes or findings of chronicity or acuity were seen. IMHMV, a rare disease with a mixed presentation, poses a significant diagnostic challenge to clinicians and pathologists.

23 November 2017 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
AWAnnika L. Windon
Annika L. Windon
SSStuti G. Shroff
Stuti G. Shroff
Background. Kaposi’s sarcoma (KS) is a vascular tumor arising in association with human herpesvirus–8 (HHV-8) infection, and different variants show different clinical presentations. Isolated intestinal KS in the background of Crohn’s disease (CD) is exceedingly rare with only 3 cases reported in the English literature (from 1966 to 2016). Case Presentation. Herein, we report a case of intestinal KS in a 21-year-old HIV-negative Ethiopian male with a long-standing history of steroid therapy for his underlying IgA nephropathy. Recent gastrointestinal biopsies confirmed an additional diagnosis of CD. Despite the addition of Infliximab to his therapy, his CD remained refractory, and a laparoscopic-assisted ileocolectomy was performed to alleviate a partial small bowel obstruction. Examination of his terminal ileum demonstrated a polypoid mass with adjacent incidental ileal submucosal nodules. These nodules were composed of plump spindle cells with scattered mitoses and vascular channels with extravasated red blood cells. Intratumoral hyaline globules were also noted. Immunohistochemistry revealed HHV-8 positivity, confirming the histologic impression of KS. Conclusions. Here we report the fourth case of KS in CD in an HIV-negative patient and only the third case of isolated intestinal KS in the setting of CD. A review of the literature suggests that attenuation of immunosuppressive therapy may be adequate management of iatrogenic KS in the absence of a systemic HHV-8 infection.